Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2009 2
2010 1
2011 3
2012 6
2013 5
2014 6
2015 6
2016 6
2017 2
2018 6
2019 2
2020 4
2021 3
2022 5
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Platzbecker U, et al. Among authors: jonasova a. Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10. Lancet. 2023. PMID: 37311468 Clinical Trial.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Platzbecker U, et al. Among authors: jonasova a. Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048786 Clinical Trial.
NQO1*2 polymorphism predicts overall survival in MDS patients.
Moudra A, Minarik L, Vancurova M, Bartek J, Hodny Z, Jonasova A. Moudra A, et al. Among authors: jonasova a. Br J Haematol. 2019 Jan;184(2):305-308. doi: 10.1111/bjh.15088. Epub 2018 Jan 24. Br J Haematol. 2019. PMID: 29363755 Free article. No abstract available.
Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways.
Minařík L, Pimková K, Kokavec J, Schaffartziková A, Vellieux F, Kulvait V, Daumová L, Dusilková N, Jonášová A, Vargová KS, Králová Viziová P, Sedláček R, Zemanová Z, Stopka T. Minařík L, et al. Among authors: jonasova a. Cells. 2022 Jan 11;11(2):223. doi: 10.3390/cells11020223. Cells. 2022. PMID: 35053339 Free PMC article.
Improved hematopoietic stem cell transplantation upon inhibition of natural killer cell-derived interferon-gamma.
Lobo de Figueiredo-Pontes L, Adamcova MK, Grusanovic S, Kuzmina M, Aparecida Lopes I, Fernandes de Oliveira Costa A, Zhang H, Strnad H, Lee S, Moudra A, Jonasova AT, Zidka M, Welner RS, Tenen DG, Alberich-Jorda M. Lobo de Figueiredo-Pontes L, et al. Among authors: jonasova at. Stem Cell Reports. 2021 Aug 10;16(8):1999-2013. doi: 10.1016/j.stemcr.2021.06.008. Epub 2021 Jul 8. Stem Cell Reports. 2021. PMID: 34242616 Free PMC article.
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.
Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, Olíva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A. Garcia-Manero G, et al. Among authors: jonasova a. J Clin Oncol. 2021 May 1;39(13):1426-1436. doi: 10.1200/JCO.20.02619. Epub 2021 Mar 25. J Clin Oncol. 2021. PMID: 33764805 Free PMC article. Clinical Trial.
Nature of frequent deletions in CEBPA.
Fuchs O, Kostecka A, Provaznikova D, Krasna B, Brezinova J, Filkukova J, Kotlin R, Kouba M, Kobylka P, Neuwirtova R, Jonasova A, Caniga M, Schwarz J, Markova J, Maaloufova J, Sponerova D, Novakova L, Cermak J. Fuchs O, et al. Among authors: jonasova a. Blood Cells Mol Dis. 2009 Nov-Dec;43(3):260-3. doi: 10.1016/j.bcmd.2009.07.001. Epub 2009 Aug 3. Blood Cells Mol Dis. 2009. PMID: 19651529
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.
Kaisrlikova M, Vesela J, Kundrat D, Votavova H, Dostalova Merkerova M, Krejcik Z, Divoky V, Jedlicka M, Fric J, Klema J, Mikulenkova D, Stastna Markova M, Lauermannova M, Mertova J, Soukupova Maaloufova J, Jonasova A, Cermak J, Belickova M. Kaisrlikova M, et al. Among authors: jonasova a. Leukemia. 2022 Jul;36(7):1898-1906. doi: 10.1038/s41375-022-01584-3. Epub 2022 May 3. Leukemia. 2022. PMID: 35505182 Free PMC article.
Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1.
Trsova I, Hrustincova A, Krejcik Z, Kundrat D, Holoubek A, Staflova K, Janstova L, Vanikova S, Szikszai K, Klema J, Rysavy P, Belickova M, Kaisrlikova M, Vesela J, Cermak J, Jonasova A, Dostal J, Fric J, Musil J, Dostalova Merkerova M. Trsova I, et al. Among authors: jonasova a. Mol Oncol. 2023 Dec;17(12):2565-2583. doi: 10.1002/1878-0261.13486. Epub 2023 Jul 17. Mol Oncol. 2023. PMID: 37408496 Free PMC article.
55 results